Since the work of Goldblatt, Lynch, Hanzal, and Summerville which related renal ischemia causally to hypertension (1) , it has seemed logical to use renal vasodilators in the treatment of the syndrome. Yet the pyrogens are the only substances which heretofore have been demonstrated to increase consistently renal blood flow and these have not been found suitable for therapeutic use (2, 3) . Chemical or hormonal compounds proposed as anti-hypertensive agents either exert a negligible effect on the renal circulation or reduce renal blood flow while lowering arterial pressure. These include the adrenergic blocking agent dibenamine (4, 5) , the benzodioxanes (6), the ergot alkaloids (7) , and the imidazolines (6, 8) . Xanthine derivatives, of which aminophylline may be considered the prototype, induce renal hyperemia only in congestive cardiac failure (9, 10) . The commonly used peripheral vasodilators-nicotinic acid, histamine, and the nitrites-similarly fail to augment renal blood (3, 11 ).
l-Hydrazinophthalazine (Ciba BA-5968 or Apresoline) is the basic chemical compound and one of several substituted compounds which have in common the properties of (a) increasing renal blood flow and (b) reducing arterial pressure in both animals and man (12) (13) (14) (15) (16) .
It has been shown that this drug antagonizes the pressor action of epinephrine and to a lesser extent that of nor-epinephrine (14, (17) (18) (19) (20) . It abolishes the pressor effect brought about by centripetal vagus stimulation and thought due to serotonin (21) , and it has an inhibitory effect against the National Heart Institute, U the pressor action of angiotonin and possibly other factors causally related to hypertension (22) (23) (24) . It modifies the pressor response to the cold pressor test and the overshoot following the Valsalva maneuver (24) . It causes increased coronary blood flow in the canine heart lung preparation (25) . The site of action is unknown but it has been suggested that this drug reduces the outflow of sympathetic vasopressor impulses by central action (26) . It was the purpose of this study to measure and to evaluate certain cardiovascular and renal adjustments induced by this compound in normal and in hypertensive subjects.
METHOD
A total of 27 patients were studied. All were given l-hydrazinophthalazine in rapid single intravenous doses of 0.25 -0.50 mgm./Kg./body weight. Basal determinations of blood pressure and pulse were made before administration of the drug and these were repeated every 30 seconds to five minutes for one to two hours thereafter, depending upon the rate of change.
Renal plasma flow (CPAH) and glomerular filtration rate (CIN) were simultaneously measured in 16 patients by the conventional clearance techniques (27) .4 All values before administration of the drug represent the average of at least three successive urine collection periods of 12-20 minutes each. Following administration of the drug several additional successive collections of similar duration were made.
Cardiac catheterization was performed in four healthy normotensive, non-hospitalized subjects and in two patients with hypertensive heart disease. Cardiac output, vascular resistance and work load were determined during the basal state and at intervals following administration of l-hydrazinophthalazine up to two hours. Cardiac output was measured by the usual determination of oxygen consumption and A-V oxygen difference.
Electrocardiograms were recorded serially in three normal subjects. In ten normal subjects skin temperatures were recorded simultaneously over six positions by means of an automatically recording potentiometer. Readings were made continuously in a constant temperature room at Centigrade in the post-absorptive state for several hours before and after intravenous or intraarterial injection of the compound. RESULTS 
1) Renal function
The renal plasma flow increased in 12 of 16 subjects, the average maximum increase being 38%o (11-122%) (Figure 1 failing to demonstrate an increase in renal plasma flow, three had severe benign essential hypertension and manifested a pronounced and sustained fall in arterial pressure to shock levels in the recumbent position with consequent temporary but almost complete cessation of renal blood flow in two of the patients ( Figure 2 ). The fourth patient had rheumatic heart disease with mitral stenosis and aortic insufficiency and was in incipient congestive cardiac failure. Of the 12 patients in whom the renal plasma flow increased, five were normotensive and the average maximum rise was 48%o in this group. Four patients had essential hypertension with an average maximum No consistent change in glomerular filtration rate occurred; it follows, therefore, that the filtration fraction was decreased (Table I) . A diuretic action was a frequent but inconstant effect.
2) Arterial pressure
In eight normotensive subjects no consistent change in the level of systolic arterial pressure was noted while in the hypertensive group systolic pressures fell regularly following the administration of this compound (Table II) . The fall in pressure in this group averaged 66 mm. Hg and was statistically highly significant (t = 3.55, p < 0.01).
A diastolic blood pressure fall was a constant finding and in eight normotensive subjects diastolic arterial pressures decreased an average of 18 mm. Hg (t = 3.18, p < 0.01). The average maximum diastolic fall in the hypertensive group of patients was 50 mm. Hg (range 15-95). The maximum diastolic fall in both groups occurred within an average of 20 minutes and rarely returned to the pre-drug level within an hour, often not before two hours or longer. If the three patients are excluded who responded to the drug with sharp diminution of renal blood flow to shock levels, the average fall in diastolic pressure in the remaining hypertensive patients was 30 mm. Hg, excluding one patient in whom renal studies were not available but who demonstrated a severe reduction in arterial pressure from 180/90 to 80/46. Whenever measured, no fall in pressure was noted in the pulmonary circulation (see below).
Tachycardia was an almost constant occurrence although occasionally excessive bradycardia was observed. Frequent minor side effects were noted. Of these, palpitation, transient light headedness, frontal headache, flushing of the head and neck, nausea and vomiting, and circumoral numbness were most common. These symptoms were accentuated in the upright position and orthostatic accentuation of the hypotension was usually present.
With the exception of the sinus tachycardia previously noted, there were no electrocardiographic abnormalities observed throughout serial recordings in three normal subjects.
3) Skin temperature
Skin temperature studies were performed in eight patients, only one of whom was subjected to other Apresoline studies. The intravenous injection of the drug to five patients at constant temperature of 22-330C. failed to increase the skin temperatures of the extremities. In one patient two separate intra-arterial injections of 0. 
4) Cardiac output
In four healthy normotensive subjects the cardiac output was sharply increased by i-hydrazinophthalazine (Table III, Figure 4) . The maximum increase in cardiac output in the four cases occurred in 15 to 45 minutes after the drug was administered and then slowly declined. Cardiac output rose an average of 110%o. The output increased disproportionately to the tachycardia so that the stroke volume increased an average of 66%o. The mean pulmonary artery pressure changed slightly from an average of 11 mm. Hg to 16 mm. Hg. Because of the excessive rise in cardiac output the calculated total pulmonary resistance fell by an average of 27%o when the appropriate formulae were employed. The total systemic resistance, on the other hand, decreased an average of 61%o due to the fall in arterial pressure concomitant with a rise in output.
Because pulmonary artery pressures did not share in the peripheral vasodilatation the right ventricular work was disproportionately increased over the left ventricular work so that the ratio LVW/RVW was reduced by one-half.
In two patients with hypertensive heart disease, who had previously been in congestive failure, cardiac output increased only 17%o (1.23 l-Hydrazinophthalazine lowers arterial diastolic pressure when administered intravenously and with equal dosage the fall in pressure is proportionately greater in hypertensive subjects than in normal individuals. Systolic pressure declined only in the hypertensive patients. Renal blood flow increased in all normal subjects but in contrast to the fall in pressure the increase was more striking in the normal than in patients with hypertension or heart disease. The difference between these groups was found to be statistically significant. These observations do not support the assumption that lowering of arterial pressure was mediated by an increase in renal blood flow. The two actions are apparently not interdependent.
The fall in arterial pressure was not caused by uniform vasodilatation. Pulmonary artery pressure did not fall and the intravenous injection of a hypotensive dose of Apresoline failed to cause a significant elevation in skin temperature when measurements were made over widely divergent areas. Its local vasodilating action could be demonstrated, however, by injecting large amounts of the drug intra-arterially. The fall in pressure is not the result of a lowered cardiac output in either normal or hypertensive subjects in whom adequate studies were available. It appears likely that selective vasodilatation, presumably of the splanchnic vessels, is responsible for the observed decrease in peripheral resistance.
The sharp increase in cardiac output and stroke volume in normal subjects together with the fall in pressure is of interest. The per cent increase in cardiac output exceeded the per cent increase in renal blood flow. Though measurements were not obtained simultaneously or in the same individuals, it does not appear likely that the results are random variations (Tables I, III ). In the light of these observations a relative decrease in renal blood flow may be considered the renal pattern of this compound. That is, renal blood flow increases, though to a lesser extent than the systemic blood flow.
The cardiovascular adjustments, characterized by an excessive decrease in total arteriolar resistance, are reminiscent of those observed following the administration of epinephrine in subjects in whom the vasoexcitor components of epinephrine have been blocked by dibenamine and who demonstrate Dale's blood pressure reversal in the face of increased cardiac output (28) . It 
